European Journal of Molecular & Clinical Medicine

ISSN 2515-8260 Volume 9, Issue 2, Winter 2022

ORIGINAL RESEARCH

A COMPARATIVE STUDY OF LABETALOL AND NIFEDIPINE IN THE MANAGEMENT OF HYPERTENSIVE DISORDERS OF PREGNANCY

[1]Akaraonye, Mercy. A, [2]Confesora Valdez Aquino, [3]Chinelo Igweike, [4]Adaugo Nwanguma, [5]Ayesha Fonseca, [6]Luwaji Aderinmola, [7]Oluwaseun Christiannah Konigbagbe, [8]Srinidhi Cheeti

[1]Bsc. MBBCH Faculty of Clinical Sciences University of Calabar, Nigeria
[2]Universidad Autónoma de Santo Domingo (UASD), Dominican Republic
[3]University of Jos, Nigeria
[4]MPH, Nnamdi Azikiwe University, Nigeria
[5]MD, AUIS School of Medicine, Barbados
[6]MBBCh, DipObst, University of the Witwatersrand, South Africa
[7]Windsor University School of Medicine, St Kitts and Nevis
[8]Chalmeda Anand Rao Institute of Medical Sciences, Telangana, India

Correspondence:
Akaraonye, Mercy. A
Bsc. MBBCH Faculty of Clinical Sciences University of Calabar, Nigeria
Email: zaramerc19@gmail.com

ABSTRACT:

Background: Hypertensive disorders of pregnancy are one of the major causes of morbidity and mortality in both the mother and fetus. The present study was conducted to compare labetalol and nifedipine in the management of hypertensive disorders during pregnancy.
Materials & Methods: 72 pregnant between the ages of with hypertension were divided into two groups Was this a blind study? Oral Labetalol was initially started at a dose of 100 mg twice daily (BD) and a maximum dose of 200 mg thrice daily (TDS) was given. Oral What type of Nifedipine? XR, regular? was initially started with a dose of 10 mg BD and titrated upwards to 20 mg TDS. Pregnant subjects were monitored daily for blood pressure and fetal well- being.
Results: Group I received 100 mg labetalol and group II received 10 mg Nifedipine. Gravida I patients were noted to have 62% and 60%, Gravida 2, 24% and 27%, and Gravida 3 14% and 13% reduction in group I and group II respectively. The difference was significant (P< 0.05). SBP (mm Hg) before treatment was 153.4 and 152.4 and after treatment was 126.8 and 138.2 in group I and group II respectively. DBP (mm Hg) before treatment was 104.2 and 106.4 and after treatment was 90.5 and 99.2. MAP (mm Hg) before treatment was 120.2 and

122.6 and after treatment was 101.5 and 112.8 in group I and group II respectively. The difference was significant (P< 0.05).

Conclusion: Labetalol proved to be a better antihypertensive than nifedipine in controlling maternal hypertension and fetal outcome. This effect was significant in systolic blood pressure control compared to diastolic blood pressure control (p < .05) and (p <.12). This difference was also remarkable in terms of parity as shown in the chart comparing Gravida 1, 2 & 3.

Keywords: Labetalol, Nifedipine, Hypertension

INTRODUCTION:

Hypertensive disorders during pregnancy can negatively impact both the mother and fetus, and if not controlled, can often lead to an increased risk of morbidity and mortality affecting about 5-10% of all pregnancies. 1 The prevalence of chronic hypertension in pregnancy is estimated at 3%, but this number is set to increase with rising maternal age and the global obesity epidemic. Given that chronic hypertension is associated with significantly increased adverse maternal and perinatal outcomes compared with the general pregnant population, defining optimal antihypertensive treatment(s) is warranted.2Hypertensive disorders of pregnancy include preeclampsia, eclampsia, gestational hypertension, chronic hypertension, and preeclampsia superimposed on chronic hypertension. Among the hypertensive disorders, preeclampsia and eclampsia are the major causes of maternal and perinatal morbidity and mortality.3,4

In one study, results showed that tighter control of diastolic blood pressure with a target of 85 mm Hg (compared with less-tight control to a diastolic target of 105 mm Hg) did not increase the risk of pregnancy loss or high-level neonatal care in women with non-severe chronic and gestational hypertension, no proteinuria? and a singleton pregnancy.5 Overall, beta-blockers, specifically labetalol, were just as effective as other antihypertensives used during pregnancy and do not appear to be teratogenic based on current data..The present study was conducted to compare labetalol and nifedipine in management of hypertensive disorders of pregnancy.

MATERIALS & METHODS:

The present study comprised of 72 pregnant between the ages of with hypertension whose two blood pressure recordings are ≥ 140/90 mm Hg more than 6 hours apart. The consent was obtained from all enrolled patients.

Data such as name, age etc. was recorded. They were divided into two groups with each group having 36 subjects Group I received labetalol and group II received nifedipine. Labetalol was started at an initial dose of 100 mg twice daily (BD) and Was it titrated up to the max. dose of 200 mg 3 times daily? (TDS) was given. Nifedipine was started with an initial dose of 10 mg BD and the dose was increased up to 20 mg TDS. Patients were monitored Certain times in the day? for blood pressure and How was fetal well being measured? Fetal monitor?. Data was analyzed with a P value < 0.05 considered significant.

RESULTS:

Table I Distribution of patients

Groups	Group I	Group II
Drug	100 mg labetalol	10 mg Nifedipine
Number	36	36

Table I shows that group I received 100 mg labetalol and group II received 10 mg Nifedipine.

Table II Comparison of gravida

Gravida	Group I	Group II	P value
1	62%	60%	0.05
2	24%	27%	
3	14%	13%	

Table II, graph I shows the percent change in Blood Pressure control in Gravida 1, 2 and 3 in group I and group II respectively. The difference was significant (P< 0.05).

Graph I Comparison of gravida



Table III Comparison of parameters

Parameters	Variables	Group I	Group II	P value
SBP (mm Hg)	Before treatment	153.4	152.4	0.05
	After treatment	126.8	138.2	
DBP (mm Hg)	Before treatment	104.2	106.4	0.12
	After treatment	90.5	99.2	
MAP (mm Hg)	Before treatment	120.2	122.6	0.17
	After treatment	101.5	112.8	

Table III, graph I shows that SBP (mm Hg) before treatment was 153.4 and 152.4 and after treatment was 126.8 and 138.2 in group I and group II respectively. DBP (mm Hg) before treatment was 104.2 and 106.4 and after treatment was 90.5 and 99.2. MAP (mm Hg) before

treatment was 120.2 and 122.6 and after treatment was 101.5 and 112.8 in group I and group II respectively. The difference was significant (P< 0.05).

Graph I Comparison of parameters



Table III Assessment of primary outcome

Variables	Group I	Group II	P value
Time required to control blood pressure (in hours)	28.4	34.5	0.05
Sustained blood pressure control for 3 days (in %)	53.2	38.1	0.01

Table III, graph II shows that mean time required to control blood pressure (in hours) was 28.4 in group I and 34.5 in group II and sustained blood pressure control for 3 days (in %) was 53.2% in group I and 38.1% in group II. The difference was significant (P< 0.05).

Graph II Assessment of primary outcome



DISCUSSION:

Hypertensive disorders are the most common medical disorders during pregnancy and are a major cause of maternal and perinatal mortality and morbidity worldwide. "It complicates about 5-10% of all pregnancies leading to maternal morbidity and mortality." is present in our introduction. Just checking that this is still fine here i think this needs to be rephrased but I can't help because I don't really get the point we are trying to make Even if delivery is the only treatment and it leads to the disappearance of the disease, this is usually problematic below 28 weeks of gestation when the baby can be expected to be extremely immature. We found that group I received 100 mg labetalol and group II received 10 mg Nifedipine. We found that gravida I had 62% and 60%, Gravida 2 had 24% and 27%, and Gravida 3 had 14% and 13% in group I and group II respectively in blood pressure reduction. Giannubilo SR et al[10] assessed the maternal and fetal outcomes of pregnancies affected by hypertensive disorders treated with nifedipine versus labetalol. The patients were divided in the four groups: gestational hypertension (113 patients); mild preeclampsia (77 patients); severe preeclampsia (31 patients); HELLP syndrome (21 patients). They found that there was higher rate of intrauterine growth restriction infants among women treated with labetalol compared with those treated with nifedipine (38.8 vs. 15.5 %; $p<0.05$), but only in the subgroup of women affected by Gestational Hypertension and Mild Preeclampsia. In this group was also higher the rate of fetal worsening assessed by fetal heart rate tracing (33.3 vs. 14.2 %; $p<0.05$). No neonatal malformations and no differences in the rate of adverse side effects were observed.

We observed that the mean time required to control blood pressure (in hours) was 28.4 in group I and 34.5 in group II and sustained blood pressure control for 3 days (in %) was 53.2% in group I and 38.1% in group II. Deshmukh et al11 compared the efficacy and safety of oral labetalol and nifedipine in hypertensive disorder of pregnancy. This study included 60 antenatal women irrespective of parity and gestational age from 20-40 weeks with hypertensive disorder. Chronic hypertension, diabetes, cardiac, renal disease, hemophilia and bronchial asthma were excluded from the study. The efficacy of labetalol and nifedipine were compared. Results: In this study fall in systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) in labetalol group was statistically significant when compared to nifedipine. Outcome of fetus was also better with use nice that we specified "oral labetalol" here. We should probably make that clear at the beginning as well as also clarifying if we used long acting vs short acting nifedipine of We also found that there is a remarkable difference in blood pressure control when compared to parity. In this research, blood pressure control trended up as the parity increased. This finding needs further investigation to identify the particular attributes that may have been a factor in this.

Webster et al[12] included 112 women (98%) who completed the study (labetalol n=55, nifedipine n=57). Maximum blood pressure after randomization was 161/101 mmHg with labetalol versus 163/105 mmHg with nifedipine (mean difference systolic: 1.2 mmHg [−4.9 to 7.2 mmHg], diastolic: 3.3 mmHg [−0.6 to 7.3 mmHg]). Mean blood pressure was 134/84 mmHg with labetalol and 134/85 mmHg with nifedipine (mean difference systolic: 0.3 mmHg [−2.8 to 3.4 mmHg], and diastolic: −1.9 mmHg [−4.1 to 0.3 mmHg]). Nifedipine use was associated with a 7.4-mmHg reduction (−14.4 to −0.4 mmHg) in central aortic pressure,

measured by pulse wave analysis. No difference in treatment effect was observed in black women (n=63), but a mean 4 mmHg reduction (−6.6 to −0.8 mmHg; P=0.015) in brachial diastolic blood pressure was observed with labetalol compared with nifedipine in non-black women (n=49). Labetalol and nifedipine control mean blood pressure to target in pregnant women with chronic hypertension.

CONCLUSION:

Authors found that labetalol is a better antihypertensive than nifedipine in terms of control of hypertension and fetal outcome.

REFERENCES:

1. Stott D, Bolten M, Salman M, Paraschiv D, Douiri A, Kametas NA. A prediction model for the response to oral labetalol for the treatment of antenatal hypertension. Journal of human hypertension, 2016; 31(2): 126-31.
2. Raheem A, Saaid R, Omar S, Tan PC. Oral nifedipine versus intravenous labetolol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomized trial. BJOG. 2012;119(1):78-85.
3. Cairns AE, Pealing L, Duffy JMN, Roberts N, Tucker KL, Leason P, et al. Post-partum management of hypertensive disorders of pregnancy: a systematic review. BMJS Open. 2017;7(11):e18696.
4. Veena P, Perivela L, Raghavan SS. Furosemide in Postpartum management of severe pre-eclampsia: a randomized controlled trial. Hyperten Pregnancy. 2017;36(1):84-9.
5. Vermillion ST, Scardo JA, Newmann RB, Chauhan SP. A randomized double blind trial of oral nifedipine and intravenous labetolol in hypertensive emergencies of pregnancy. Am J Obstet Gynaecol. 1999;181(4):858-61.
6. Sharma KJ, Greene N, Kilpatrick SJ. Oral Labetolol compared to oral nifedipine for post-partum hypertension. A randomized controlled trial. Hyperten Pregnancy. 2017; 36(1): 44-7. Patel NK, Gadhavi M, Gorasia D, Pandya MR. Comparative evaluation of antihypertensive drugs in the management of pregnancy-induced hypertension. Int J Basic Clin Pharmacol. 2012; 1:174-7.
7. Shekhar S, Sharma C, Thakur S, Verma S. Oral Nifedipine or Intravenous Labetalol for hypertensive emergency in pregnancy: a randomized controlled trial. Obstetrics & Gynecology. 2013; 122(5):1057-63.
8. Hangarga US, Rita D, Harshitha K. Comparative study of labetalol and nifedipine in management of hypertensive disorders in pregnancy. International Journal Reproduction Contraception, Obstetrics Gynecology. 2017; 6:194-7.
9. Michael CA. The evaluation of labetalol in the treatment of hypertension complicating pregnancy. British journal of clinical pharmacology. 1982; 1:13(S1).
10. Giannubilo SR, Bezzeccheri V, Cecchi S, Landi B, Battistoni GI, Vitali P, Cecchi L, Tranquilli AL. Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Archives of gynecology and obstetrics. 2012 Sep;286(3):637-42.
11. Deshmukh UB, Savitha A, Tengli S. Comparative study of labetalol and nifedipine in management of hypertensive disorders of pregnancy in BRIMS tertiary care center. The New Indian Journal of OBGYN. 2021; 8(1): 117-20.

12. Webster LM, Myers JE, Nelson-Piercy C, Harding K, Cruickshank JK, Watt-Coote I, Khalil A, Wiesender C, Seed PT, Chappell LC. Labetalol versus nifedipine as antihypertensive treatment for chronic hypertension in pregnancy: a randomized controlled trial. Hypertension. 2017 Nov;70(5):915-22.